Abstract: A method of manufacturing a nitride semiconductor and a nitride semiconductor thin film prepared using the method are provided. The method includes preparing a substrate, forming a buffer layer by growing a thin film having a three-dimensional (3D) structure on the substrate, and forming a nitride semiconductor layer on the buffer layer.

Abstract: A method of manufacturing a nitrogen (N)-face nitride semiconductor and an N-face nitride semiconductor device manufactured using the method are provided. The method includes preparing a substrate, and forming a nitrogen-polarization (N-polar) nitride semiconductor layer on the substrate, using a pulse growth mode. The forming of the N-polar nitride semiconductor layer may include supplying a Group V element precursor, a Group III element precursor, or both in a pulse mode in a vapor deposition process.

Abstract: An all-solid-state battery having an increased lifespan is equipped with a pressure pad layer. More particularly, the all-solid-state battery includes a unit cell and a pressuring pad layer. The unit cell is composed of a cathode, an anode, and a solid electrolyte layer positioned between the cathode and the anode. The pressurizing pad layer is positioned on each side of the unit cell and includes a non-porous upper layer, a non-porous lower layer, and a porous core layer positioned between the non-porous upper layer and the non-porous lower layer.

Abstract: A heat dissipation material is provided. In the heat dissipation material with a filler, comprising secondary particles in which primary particles are aggregated, the filler in a polymer resin matrix may form a thermal interface layer for conduction of thermal energy between a heat generation part and a heat absorption part.

Abstract: The present invention relates to a preparation method for an animal model with Alzheimer's disease by injecting a human mutant tau (AAV-hTau) vector and adenovirus into an animal. The preparation method for an AD animal model provided by the present invention may contribute to the development of the field of treatment technology for treating AD since the preparation method causes AD pathology to appear as early as 8 months old and facilitates studies on AD target treatment strategies and tau pathology.

Abstract: The present invention relates to a pharmaceutical composition comprising (S)-2-(((4?-trifluoromethylbiphenyl-4-yl)methyl)amino)propanamide methanesulfonate or a pharmaceutically acceptable salt thereof as an effective ingredient for prevention or treatment of stroke.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same, for treating a neurodegenerative diseases.

Abstract: The present disclosure relates to an ?-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.